公开(公告)号：EP2427193A4

公开(公告)日：2013-04-03

申请号：EP10772372

申请日：2010-05-03

申请人： OMEROS CORP

发明人： BERGMANN JOHN E ,  CUTSHALL NEIL S ,  DEMOPULOS GREGORY A ,  FLORIO VINCENT A ,  GAITANARIS GEORGE ,  GRAY PATRICK ,  HOHMANN JOHN ,  ONRUST RENE ,  ZENG HONGKUI

IPC分类号： A61K31/50 ,  A61K31/137 ,  A61K31/195 ,  A61K31/38 ,  A61K31/415 ,  A61K31/425 ,  A61K31/433 ,  A61K31/519 ,  A61K31/527 ,  A61K45/06 ,  A61P25/14 ,  C07D471/04

CPC分类号： A61K31/551 ,  A61K31/00 ,  A61K31/085 ,  A61K31/122 ,  A61K31/137 ,  A61K31/192 ,  A61K31/195 ,  A61K31/198 ,  A61K31/381 ,  A61K31/4025 ,  A61K31/4162 ,  A61K31/425 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/4985 ,  A61K31/505 ,  A61K31/506 ,  A61K31/519 ,  A61K31/527 ,  A61K31/542 ,  A61K45/06 ,  C07D471/04 ,  A61K2300/00

摘要： A method of treating a movement abnormality associated with the pathology of a neurological movement disorder, such as Parkinson's disease or Restless Leg(s) Syndrome by administering a therapeutically effective amount of a PDE7 inhibitory agent. An aspect of the invention provides for the administration of a PDE& inhibitory agent in conjunction with a dopamine agonist or precursor, such as levodopa. In another aspect of the invention, the PDE7 inhibitory agent may be selective for PDE7 relative to other molecular targets (i) known to be involved with the pathology of Parkinson's disease or (ii) at which other drug(s) that are therapeutically effective to treat Parkinson's disease act.

公开(公告)号：EP2139475A4

公开(公告)日：2012-03-07

申请号：EP08744515

申请日：2008-03-27

申请人： OMEROS CORP

发明人： BERGMANN JOHN E ,  CUTSHALL NEIL S ,  DEMOPULOS GREGORY A ,  FLORIO VINCENT A ,  GAITANARIS GEORGE ,  GRAY PATRICK ,  HOHMANN JOHN ,  ONRUST RENE ,  ZENG HONGKUI

IPC分类号： A61K31/435 ,  A61K31/195 ,  A61K31/433 ,  A61K31/519 ,  A61K31/527

CPC分类号： A61K31/195 ,  A61K31/433 ,  A61K31/519 ,  A61K31/527